VCYT News
Natera Gains 118.1% in a Year: What's Driving the Rally?
NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.
Zacks
Natera Gains 118.1% in a Year: What's Driving the Rally?
NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.
Zacks
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
VEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug development processes.
Zacks
ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
Zacks
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
VEEV's strong second-quarter results, Vault CRM migrations and AI expansion support growth, while market saturation remains a key concern.
Zacks
Is it the Right Time to Add Phibro Stock to Your Portfolio?
PAHC's Animal Health gains from MFA, vaccine and mineral nutrition growth, but tariffs, costs and currency swings remain key risks to its outlook.
Zacks
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
SNN expands CARTIHEAL's reach across 12 European markets, backed by five-year clinical data and strong momentum in its Sports Medicine Joint Repair business.
Zacks
Bruker Gains 66.3% in a Year: What's Driving the Rally?
BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.
Zacks
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook support momentum, though cybersecurity risks remain a concern.
Zacks
Veeva's DQS Scales Data Automation Across 1,000+ Clinical Studies
VEEV's DQS cleans clinical trial data for over 1 million subjects across 1,000+ studies, expanding automation in clinical data management.
Zacks
Reasons to Add Globus Medical Stock to Your Portfolio Now
GMED gains musculoskeletal share on strong spine and trauma growth, while product innovation and a debt-free balance sheet support its appeal.
Zacks